AnaptysBio (NASDAQ:ANAB) had its price objective lifted by analysts at Royal Bank of Canada to $108.00 in a note issued to investors on Monday. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price objective would indicate a potential upside of 17.44% from the stock’s previous close.
Several other research firms have also recently commented on ANAB. Zacks Investment Research upgraded AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research note on Wednesday, September 13th. Wedbush restated an “outperform” rating and issued a $75.00 target price (up previously from $37.00) on shares of AnaptysBio in a research note on Friday, October 13th. Jefferies Group began coverage on AnaptysBio in a research note on Thursday, November 9th. They issued a “buy” rating and a $101.00 target price on the stock. Stifel Nicolaus restated a “buy” rating and issued a $35.00 target price on shares of AnaptysBio in a research note on Tuesday, September 12th. Finally, Robert W. Baird set a $69.00 target price on AnaptysBio and gave the company a “buy” rating in a research note on Wednesday, October 11th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. AnaptysBio currently has a consensus rating of “Buy” and a consensus target price of $88.00.
Shares of AnaptysBio (NASDAQ ANAB) traded up $3.21 on Monday, hitting $91.96. The company had a trading volume of 1,927,700 shares, compared to its average volume of 221,524. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.77 and a quick ratio of 10.77. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $93.41.
Several institutional investors have recently made changes to their positions in ANAB. Evercore Wealth Management LLC bought a new stake in shares of AnaptysBio during the 3rd quarter worth approximately $100,000. Legal & General Group Plc grew its holdings in AnaptysBio by 160.8% in the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 1,951 shares in the last quarter. Bank of America Corp DE acquired a new position in AnaptysBio in the 1st quarter valued at $123,000. DAFNA Capital Management LLC grew its holdings in AnaptysBio by 22.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 1,000 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new position in AnaptysBio in the 2nd quarter valued at $168,000. Institutional investors own 75.48% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Royal Bank of Canada Increases AnaptysBio (ANAB) Price Target to $108.00” was posted by American Banking and Market News and is the property of of American Banking and Market News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/18/royal-bank-of-canada-increases-anaptysbio-anab-price-target-to-108-00.html.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
